Efficacy, safety, and cost of new anticancer drugs. Pessimistic conclusion was not justified
- PMID: 12458261
- PMCID: PMC1124759
- DOI: 10.1136/bmj.325.7375.1302/a
Efficacy, safety, and cost of new anticancer drugs. Pessimistic conclusion was not justified
Figures
Comment on
-
Efficacy, safety, and cost of new anticancer drugs.BMJ. 2002 Aug 3;325(7358):269-71. doi: 10.1136/bmj.325.7358.269. BMJ. 2002. PMID: 12153927 Free PMC article. No abstract available.
References
-
- Nabholz JM, Tonkin K, Smylie M, Au H-J, Lindsay M-A, Mackey J. Chemotherapy of breast cancer: are the taxanes going to change the natural history of breast cancer? Exp Opin Pharmacother. 2000;1:187–206. - PubMed
-
- Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E, et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: Three-year results. J Natl Cancer Inst. 2000;92:699–708. - PubMed
-
- Van Cutsem E, Twelves C, Cassidy J, Allman D, Bajetta E, Boyer M, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol. 2001;19:4097–4106. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources